Sen-Jam uses its PAIR™ (Pleiotropic Anti‑Inflammatory Regulators) platform to create first‑in‑class immuno‑regulators that target the root cause of chronic systemic inflammation. By pairing validated compounds and leveraging AI‑driven analytics, the company delivers safe, oral, non‑opioid therapies that modulate immune pathways across metabolic, respiratory, and critical‑care indications, offering partners scalable solutions for prevention and treatment.
Funding
$14.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic systemic inflammation drives the majority of modern diseases, including obesity, metabolic disorders, respiratory infections, opioid dependence, and severe hospital inflammation, yet existing therapies are reactive, symptom‑focused, and often rely on opioids or broad immunosuppression.
Solution
Sen‑Jam’s PAIR™ (Pleiotropic Anti‑Inflammatory Regulators) platform delivers first‑in‑class immuno‑regulators that modulate the immune system at its biological root. By pairing proven molecules in novel combinations, the platform provides targeted, non‑opioid reduction of inflammatory pathways while preserving normal immune function. The approach is designed for safety, scalability, and oral administration, enabling use across preventive health, metabolic recovery, acute respiratory illness, and critical‑care settings. Clinical programs such as SJP‑001 (metabolic balance and hangover mitigation) and SJP‑002C (upper respiratory infections) demonstrate the platform’s ability to improve outcomes and reduce disease burden. AI‑driven analytics accelerate molecule selection and trial design, supporting rapid expansion of the pipeline.
Target Audience
Primary customers include pharmaceutical partners and biotech companies seeking licensed immuno‑regulators, as well as healthcare systems and hospitals that need safe anti‑inflammatory therapies for metabolic, respiratory, and critical‑care applications.
Features
- Proprietary PAIR™ technology that combines multiple validated compounds to achieve synergistic anti‑inflammatory effects
- Non‑opioid, non‑suppressive mechanism that modulates immune response without compromising host defense
- Oral formulations suitable for consumer wellness, prescription, and hospital use
- AI‑enabled target identification and repurposing pipeline to accelerate development
- Broad therapeutic scope covering metabolic overload, opioid withdrawal, respiratory infections, and critical‑care inflammation
- Extensive IP portfolio with 60+ patents and pending applications protecting platform and specific indications